FDA Approves Pfizer ' s Supplemental New Drug Application for Cibinqo (abrocitinib) to Include Adolescents with Moderate-to-Severe Atopic Dermatitis

Label expansion for Cibinqo provides new systemic oral option for adolescents (12 to<18 years) with moderate-to-severe atopic dermatitis NEW YORK--(BUSINESS WIRE) February 10, 2023 -- Pfizer Inc. (NYSE: PFE) announced today that the United...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news